308430 — Cellbion Co Income Statement
0.000.00%
Last trade - 00:00- KR₩196bn
- KR₩169bn
- KR₩2bn
Annual income statement for Cellbion Co, fiscal year end - December 31st, KRW millions except per share, conversion factor applied.
2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | PROSPECTUS | PROSPECTUS | Annual Audited Accounts |
| Standards: | IFRS | IFRS | IFRS | IFRS |
| Status: | Final | Final | Final | Final |
| Revenue | ||||
| Total Revenue | 917 | 1,763 | 1,471 | 2,290 |
| Cost of Revenue | ||||
| Gross Profit | -118 | 208 | 314 | 967 |
| Selling / General / Administrative Expenses | ||||
| Research And Development | ||||
| Depreciation and Amortization | ||||
| Unusual Expense / Income | ||||
| Total Operating Expenses | 5,467 | 6,902 | 5,251 | 9,426 |
| Operating Profit | -4,550 | -5,139 | -3,780 | -7,137 |
| Gain / Loss on Sale of Assets | ||||
| Total Net Non Operating Interest Income / Expense | ||||
| Other Net Non Operating Costs | ||||
| Net Income Before Taxes | -4,778 | -6,382 | -3,633 | -7,266 |
| Provision for Income Taxes | ||||
| Net Income After Taxes | -4,778 | -6,382 | -3,633 | -7,266 |
| Net Income Before Extraordinary Items | ||||
| Net Income | -4,778 | -6,382 | -3,633 | -7,266 |
| Income Available to Common Shareholders Excluding Extraordinary Items | ||||
| Income Available to Common Shareholders Including Extraordinary Items | ||||
| Diluted Net Income | -4,778 | -6,382 | -3,633 | -7,266 |
| Diluted Weighted Average Shares | ||||
| Basic EPS Including Extraordinary Items | ||||
| Diluted EPS Including Extraordinary Items | ||||
| Diluted EPS Excluding Extraordinary Items | ||||
| Normalised Income Before Taxes | ||||
| Normalised Income After Taxes | ||||
| Normalised Income Available to Common Shareholders | ||||
| Diluted Normalised EPS | -375 | -514 | -385 | -716 |
| Dividends per Share |